Thursday, January 23, 2025 3:24:05 PM
Thanks to Cycl2R for this nugget:
Re Gates and us
The quote below from an overall critical piece about the Gates Foundation might be of interest in case it's them who have taken almost 20% of our company.
"The foundation has put $500 million into its own nonprofit pharmaceutical enterprise, the Gates Medical Research Institute, according to Schwab, and it makes hundreds of millions of dollars in charitable gifts directly to for-profit pharmaceutical companies “in which the foundation’s endowment reported holding stocks and bonds, like Merck, Pfizer, and Novartis. This means the foundation is sometimes positioned to benefit financially from its charitable partnerships.”
Through its grant contracts and ownership stakes in pharmaceutical companies big and small, the elite foundation aggressively, and coercively, acquires useful knowledge about the intellectual property underlying all of the pharmaceutical products whose development it finances. In the education of policymakers and the public, it steadfastly defends the patent-system structure in which intellectual-property rights are exercised and monetized by it and Big Pharma, if those are even separate. It protects and defends specific patents in always implicitly threatened or occasionally actual lawsuits, as well.”
Re Gates and us
The quote below from an overall critical piece about the Gates Foundation might be of interest in case it's them who have taken almost 20% of our company.
"The foundation has put $500 million into its own nonprofit pharmaceutical enterprise, the Gates Medical Research Institute, according to Schwab, and it makes hundreds of millions of dollars in charitable gifts directly to for-profit pharmaceutical companies “in which the foundation’s endowment reported holding stocks and bonds, like Merck, Pfizer, and Novartis. This means the foundation is sometimes positioned to benefit financially from its charitable partnerships.”
Through its grant contracts and ownership stakes in pharmaceutical companies big and small, the elite foundation aggressively, and coercively, acquires useful knowledge about the intellectual property underlying all of the pharmaceutical products whose development it finances. In the education of policymakers and the public, it steadfastly defends the patent-system structure in which intellectual-property rights are exercised and monetized by it and Big Pharma, if those are even separate. It protects and defends specific patents in always implicitly threatened or occasionally actual lawsuits, as well.”
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
